多发性骨髓瘤患者造血细胞中的嵌合染色体改变与临床结局
研究纳入976例接受大剂量化疗和自体干细胞支持(ASCT)的多发性骨髓瘤患者,中位随访6.4年,在158例(16.2%)的干细胞采集物中检出嵌合染色体改变(mCAs)。常染色体mCAs携带者与非携带者的总生存和进展相似;女性X染色体丢失者总生存更长(年龄调整HR 0.54,95%CI 0.32-0.93,p=0.02)、进展风险更低(年龄调整HR 0.55,95%CI 0.35-0.87,p=0.01)且移植后缓解更好;多个mCAs者总生存更差(年龄调整HR 2.0,95%CI 1.02-3.84,p=0.04)且进展风险更高(年龄调整HR 3.36,95%CI 1.67-6.81,p<0.001)。
要点
- 干细胞采集物中mCAs检出率为16.2%(158/976例)。
- 女性X染色体丢失与更长总生存和更低进展风险相关。
- 多个mCAs与更差总生存和更高进展风险相关。
核心结论
- 常染色体mCAs携带者与非携带者的总生存和进展相似;女性X染色体丢失者总生存更长、进展风险更低且移植后缓解更好;多个mCAs者总生存更差且进展风险更高,推测由疑似骨髓瘤污染驱动。
研究设计与样本
- 研究纳入976例接受大剂量化疗和自体干细胞支持(ASCT)的多发性骨髓瘤患者,中位随访6.4年,检测干细胞采集物中的mCAs。
主要发现
- 158例(16.2%)检出mCAs;60例(6.1%)检出常染色体异常并累及所有染色体。
- 51例女性(12.7%)检出X染色体丢失,55例男性(9.6%)检出Y染色体丢失。
- 女性X染色体丢失者总生存更长(年龄调整HR 0.54,95%CI 0.32-0.93,p=0.02)。
- 女性X染色体丢失者进展风险更低(年龄调整HR 0.55,95%CI 0.35-0.87,p=0.01),且移植后缓解更好(完全缓解(CR)或非常好的部分缓解(VGPR)程度更高)。
- 多个mCAs者总生存更差(年龄调整HR 2.0,95%CI 1.02-3.84,p=0.04)且进展风险更高(年龄调整HR 3.36,95%CI 1.67-6.81,p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mosaic chromosomal alterations (mCAs) in hematopoietic cells increase mortality and risk of hematological cancers and infections. We investigated the landscape of mCAs and their clinical consequences in 976 patients with multiple myeloma undergoing high-dose chemotherapy and autologous stem cell support (ASCT) with median 6.4 years of follow-up. mCAs were detected in the stem cell harvest product of 158 patients (16.2%). Autosomal aberrations were found in 60 patients (6.1%) and affected all chromosomes. Loss of chromosome X was found in 51 females (12.7%) and loss of chromosome Y in 55 males (9.6%). Overall survival and progression were similar between carriers of autosomal mCAs and non-carriers. In contrast, female patients with loss of the X chromosome had longer overall survival (age-adjusted[a.a.] HR 0.54, 95% CI 0.32-0.93, p = 0.02), lower risk of progression (a.a. HR 0.55, 95% CI 0.35-0.87; p = 0.01), and better post-transplant response (higher degree of complete response (CR) or very good partial response (VGPR)). The reason for this substantial effect is unknown. Additionally, myeloma clones in the stem cell product was confirmed by mCA analysis in the few patients with multiple mCAs (n = 12 patients). Multiple mCAs conferred inferior overall survival (a.a. HR 2.0, 95% CI 1.02-3.84; p = 0.04) and higher risk of myeloma progression (a.a. HR 3.36, 95% CI 1.67-6.81; p < 0.001), which is presumed to be driven by suspected myeloma contaminants.
引用
- Husby S, Tulstrup M, Harsløf M, et al. Mosaic chromosomal alterations in hematopoietic cells and clinical outcomes in patients with multiple myeloma. Leukemia. 2024. PMID: 39223296. doi:10.1038/s41375-024-02396-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。